No Detail Found!

Characterization of beta thalassaemia mutations in patients having borderline haemoglobin A2 levels

Author(s)
Afshan Noor Armed Forces Institute of Pathology, National University of Medical Sciences,Rawalpindi-,Pakistan
Manzar Bozdar Armed Forces Institute of Pathology, National University of Medical Sciences,Rawalpindi-,Pakistan
Hamid Saeed Malik Armed Forces Institute of Pathology, National University of Medical Sciences,Rawalpindi-,Pakistan
Rafia Mahmood Armed Forces Institute of Pathology, National University of Medical Sciences,Rawalpindi-,Pakistan
Ayesha Khurshid Armed Forces Institute of Pathology, National University of Medical Sciences,Rawalpindi-,Pakistan
Aysha Khan Armed Forces Institute of Pathology, National University of Medical Sciences,Rawalpindi-,Pakistan
Nighat Seema Department of Forensic Medicine, Ayub Medical College, Abbottabad-Pakistan
Abstract
Background: The occurrence of a single beta thalassaemia allele is frequently related with microcytic hypochromic red blood cells and a rise in HbA2 levels. In some beta thalassaemia carriers, the outcome of this allele or its collaboration with other acquired or genetic defects may result in normal or borderline Haemoglobin bA2 levels. Objective was to establish the importance of molecular analysis in borderline HbA2 individuals and its significance in a population screening program. Methods: It was a cross-sectional study conducted over a period of six months, from JulyDecember 2023. All 123 individuals with borderline HbA2 levels between (3?3.9%) diagnosed by High-performance liquid chromatography (HPLC)/Capillary Zone Electrophoresis underwent molecular testing using multiplex amplification refractory mutation system-Polymerase Chain Reaction (ARMS-PCR) to detect common beta thalassaemia mutations: Fr8-9, IVS1-5, Fr41-42, Cd15, Cd5, IVS1-1, IVS1-1, Cd30, Cd30, Fr16, IVSII-1, Del619, and CAP+1 in the Department of Haematology, Armed Forces Institute of Pathology, Rawalpindi .Statistical tests were applied to compare Red Blood Cell indices and Haemoglobin A2 values among beta thalassaemia carriers and non-carriers. Results: Among those tested, 47.1% (n=58) were found to carry Beta thalassaemia mutations. The most prevalent mutations were IVS1-5 (n=19,15.4%) and Fr8-9 (n=19,15.4%) followed by Fr41-42 (n=08,6.5%). Subjects with mutations exhibited significantly lower mean corpuscular volume and mean corpuscular haemoglobin compared to those without mutations (pvalue= <0.001). Beta thalassaemia mutations were seen more frequently when HbA2 was in range of 3.5-3.9% (n=37,63.8%), as compared to HbA2 that was 3-3.4% (n=21,36.2%) and this difference was found to be significant (p-value= <0.001). The CAP+1 mutation was associated (n=02,1.6%) with normal mean MCV and MCH compared to other identified mutations. Conclusions: It is concluded that molecular study for the common beta thalassaemia mutations in Pakistani population plays a pivotal role in confirmation of borderline HbA2 thalassaemia carriers, specifically in areas with a high prevalence of the disease. Molecular testing for beta thalassaemia should be offered to all individuals with borderline HbA2 with values especially between 3.4?3.9% and having microcytic hypochromic indices.
Publication Details
Page(s) 783-787
Published Journal: Journal of Ayub Medical College, Volume: 36, Issue: 4, Year: 2024

Request the full text from PASTIC

Keywords
Red cell indices, Molecular analysis, Silent carriers, Beta Thalassaemia mutation, Borderline HbA2
References
Moradi K,Alibakhshi R,Shafieenia S,Azimi A .2022 .Problem of borderline hemoglobin A2 levels in an Iranian population with a high prevalence of α-and β-thalassemia carriers. Egypt J Med Hum Genet, 23(1) : 61.
Paleari R,Giambona A,Cannata M,Leto F,Maggio A,Mosca A .2007 .External quality assessment of hemoglobin A2 measurement: data from an Italian pilot study with fresh whole blood samples and commercial HPLC systems. Clin Chem Lab Med, 45(1) : 88-92.
.2024 .Unresolved laboratory issues of the heterozygous state of β- thalassemia: a literature review. Haematologica, 109(1) : 23-32.
Srivorakun H,Thawinan W,Fucharoen G,Sanchaisuriya K,Fucharoen S. Thalassemia .2022 .and erythroid transcription factor KLF1 mutations associated with borderline hemoglobin A2 in the Thai population. Arch Med Sci, 18(1) : 112-20.
Zhao Y,Jiang F,Li DZ,Gene DZ,(G> A)(HBB: c DZ .2020 .-100G> A) Carriers in Mainland China. Hemoglobin, 44(4) : 240-3.
Dell'Edera D,Sarlo F,Epifania AA,Lupo MG . .When the study of the globin genes is useful? 2017.. , : .
Origa R. .2021 .. , : .
Theodoridou S,Balassopoulou A,Boutou E,Delaki EE,Yfanti E,Vyzantiadis TA .2020 .Coinheritance of triplicated alpha-globin gene and beta-thalassemia mutations in adulthood: ten years of referrals in northern Greece. J Pediatr Hematol Oncol, 42(8) : e762-4.
Khan AM,Al-Sulaiti AM,Younes S,Yassin M,Zayed H. .2021 .The spectrum of beta-thalassemia mutations in the 22 Arab countries: a systematic review. Expert Rev Hematol, 14(1) : 109-22.
Hammoud H,Ghanem R,Abdalla R,Semaan P,Azzi J,Prada EP .2020 .Genetic mutations of beta thalassemia in middle east countries. World J Pharm Pharm Sci, 9(2) : 134-50.
Thaker P,Mahajan N,Mukherjee MB,Colah RB .2024 .Wide spectrum of novel and rare hemoglobin variants in the multiethnic Indian population: A review. Int J Lab Hematol, 46(3) : 434-50.
Colaco S,Nadkarni A .2021 .Borderline HbA2 levels: dilemma in diagnosis of beta-thalassemia carriers. Mutat Res Rev Mutat Res, 788 : 108387.
Colah R,Italia K,Gorakshakar A .2017 .Burden of thalassemia in India: the road map for control. Pediatr Hematol Oncol J, 2(4) : 79-84.
Ahmed S. .2017 .Genetic haemoglobin disorders in Pakistan. Natl J Health Sci, 2(3) : 95-9.
Ansari SH,Shamsi TS,Bohray M,Khan MT,Farzana T,Perveen K .2011 .Molecular epidemiology of β-thalassemia in Pakistan: far reaching implications. Int J Mol Epidemiol Genet, 2(4) : 403-8.
Satthakarn S,Panyasai S,Pornprasert S. .2020 .Molecular characterization of β-and α-globin gene mutations in individuals with borderline hb a2 levels. Hemoglobin, 44(5) : 349-53.
Saif S,Lila S,Ghani G,Rahat MA,Rasool A,Israr M. .2024 .Clinical Insights: Prevalence of β-Thalassemia Mutations (IVSI-5. J Bio-X Res, 7(FSC8) : 0004.
Sumedha D,Anita K. .2023 .Prevalence of beta thalassemia carriers in India: a systematic review and meta-analysis. J Community Genet, 14(6) : 527-41.
Zulkeflee RH,Bahar R,Abdullah M,Mohd Radzi MAR,Md Fauzi A,Hassan R .2023 .Application of targeted next-generation sequencing for the investigation of thalassemia in a developing country: A single center experience. Diagnostics, 13(8) : 1379.
Chaweephisal P,Phusua A,Fanhchaksai K,Sirichotiyakul S,Charoenkwan P .2019 .Borderline hemoglobin A2 levels in northern Thai population: HBB genotypes and effects of coinherited alpha-thalassemia. Blood Cells Mol Dis, 74 : 13-7.
Thein SL .2013 .The molecular basis of β-thalassemia. Cold Spring Harb Perspect Med, 3(5) : a011700.
Abdul Karim MU,Moinuddin M,Babar SU .2009 .Cap+ 1 mutation; an unsuspected cause of beta thalassaemia transmission in Pakistan. Turk J Haematol, 26(4) : 167-70.
Kaur G,Chatterjee T,Ahuja A,Sen A .2024 .Challenges in diagnosis of thalassemia syndromes. Med J Armed Forces India, 80(6) : 632-7.
Tariq R,Sikandar N,Akhtar S,Bashir S,Farooq MU .2022 .Significance of Molecular Analysis in a Population Screening Program for Identification of Silent Beta Thalassemia Carriers in a Country with High Disease Prevalence. J Haematol Stem Cell Res, 2(2) : 68-72.
Rosnah B,Shahida N,Nazri M,Marini R,Noor Haslina M,Shafini M. .2017 .The diagnosis of beta thalassemia with borderline HbA2 level among Kelantan population. J Blood Disord Transfus, 8(396) : 2.
Stephanou C,Petrou M,Kountouris P,Makariou C,Christou S,Hadjigavriel M .2024 .Variant in Beta Thalassemia. Biomedicines, 12(2) : 296.
Catapano R,Sessa R,Trombetti S,Cesaro E,Russo F,Izzo P .2023 .Identification and functional analysis of known and new mutations in the transcription factor KLF1 linked with β- thalassemia-like phenotypes. Biology, 12(4) : 510.
Cheema AN,Khanum R .2020 .Impact of Iron deficiency on diagnosis of Beta Thalassemia Trait. Prof Med J, 27(04) : 849-52.
0

Citations

0

Downloads

46

Views